Head-To-Head Contrast: Genfit (OTCMKTS:GNFTF) versus Structure Therapeutics (NASDAQ:GPCR)

Genfit (OTCMKTS:GNFTF) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Profitability

This table compares Genfit and Structure Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genfit	N/A	N/A	N/A
Structure Therapeutics	N/A	-20.12%	-19.11%

Valuation & Earnings

This table compares Genfit and Structure Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genfit	N/A	N/A	N/A	($0.67)	-6.51
Structure Therapeutics	N/A	N/A	-$89.62 million	($0.77)	-54.44

Structure Therapeutics is trading at a lower price-to-earnings ratio than Genfit, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Genfit and Structure Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genfit	0	0	0	0	N/A
Structure Therapeutics	0	0	7	0	3.00

Structure Therapeutics has a consensus price target of $84.63, indicating a potential upside of 101.87%. Given Structure Therapeutics’ higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than Genfit.

Institutional and Insider Ownership

11.1% of Genfit shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 9.4% of Structure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

About Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

About Structure Therapeutics

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.